Noetik Announces First-in-Class Human Foundation Models for Discovery at SITC 2024

SAN FRANCISCO— November 7, 2024. Noetik, an AI-native biotech company leveraging self-supervised machine learning and high-throughput spatial data to develop next-generation cancer therapeutics, announced today the first two presentations of its AI-enabled drug discovery platform at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting. The posters showcase Noetik’s OCTO foundation model of cell and tissue biology and demonstrate for the first time the application of OCTO to therapeutics discovery.

‍

“Noetik’s platform brings together one of the largest multimodal spatial datasets of human tumor biology, generated in-house at Noetik labs, with custom-built self-supervised models that are trained at a scale to unlock the complexities of biology. The work at SITC showcases, for the first time, how we can use these models as powerful engines for drug discovery,” said Lacey Padron, Ph.D., Chief Technical Officer of Noetik and presenter.

‍

SITC, a leading member-driven organization dedicated to improving cancer patient outcomes by advancing cancer immunotherapy, will host its 2024 Annual Meeting from November 6th to 10th at the George R. Brown Convention Center in Houston. The abstracts will be published in the Journal for ImmunoTherapy of Cancer (JITC).

‍

‍

Details on Noetik’s poster presentations at SITC are as follows: